FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
Category: #health  By Mateen Dalal  Date: 2020-08-28
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test BinaxNOW™.

For the uninitiated, BinaxNOW™ is a portable, fast, and reliable test that uses Abbott’s lateral flow technology in order to detect antigens at a massive scale. The tool requires minimal equipment and provides test results in 15 minutes. The company plans on selling each test for $5.

As per the study conducted by Abbott along with leading research universities, the test results of the BinaxNOW COVID-19 Ag Card reflected 98.5% specificity (negative percent agreement) and 97.1% sensitivity (positive percent agreement) within the first seven days of individuals being suspected of contracting the COVID-19 virus.

The FDA marketing authorization comes after the antigen test kit was approved for use by healthcare professionals conducting point-of-care tests operating under Clinical Laboratory Improvement Amendments (CLIA) Certificates of Compliance, Certificate of Waiver as well as Certificate of Accreditation.

According to credible sources, Abbott will also launch NAVICA™, a mobile-based application compatible with Android and iOS devices. The BinaxNOW test will function on a reactive card paired with the application that is intended to work as a temporary digital health pass for individuals who test negative for Coronavirus.

Moreover, the interactive application will be free of cost and will encourage information such as social distancing and mask-wearing on the mobile devices.

CEO and President of Abbott Laboratories, Robert B. Ford, was reported saying that the two platforms launched by the company are collectively aimed at providing an affordable and convenient testing solution for the residents of U.S. in an effort to make them feel more confident about their lives and general health.

In other news, the U.S. FDA (Food and Drug Administration) has reportedly granted approval for healthcare agencies to use convalescent plasma for the treatment of the COVID-19 virus. The administration claimed that the benefits of the plasma outweigh the potential risks.

Source credits: https://www.prnewswire.com/news-releases/abbotts-fast-5-15-minute-easy-to-use-covid-19-antigen-test-receives-fda-emergency-use-authorization-mobile-app-displays-test-results-to-help-our-return-to-daily-life-ramping-production-to-50-million-tests-a-month-301119289.html

Other news: https://health.economictimes.indiatimes.com/news/pharma/us-fda-approves-blood-plasma-therapy-to-treat-covid-19/77719806

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...